Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Amgen looks like a high-quality but no longer cheap defensive asset with strong operating margins and a notable debt burden. Revenue, EBITDA, operating income, and net income have generally been growing year over year, which supports the valuation and points to business stability. The operating margin of around 30% and net margin of around 23% are very strong levels for the healthcare sector, and ROE and ROA are also high and improving compared with previous periods. At the same time, P/E, P/S, P/FCF, and especially P/B are above the industry median, which limits the potential for further re-rating and calls for caution. Debt-to-equity and the absolute amount of long-term debt remain high, increasing sensitivity to interest rates and reducing the balance sheet’s margin of safety. Liquidity is acceptable but not comfortable: the quick ratio and current ratio are above 1, but noticeably below industry benchmarks, so the balance sheet cannot be called strong. Dividend yield has declined compared with previous periods, removing some of the defensive appeal for income-oriented investors. On the other hand, the growth in cash on hand, assets, and shareholders’ equity shows that the company maintains financial resilience and continues to expand its resource base. Gross margin is slightly below the industry median, but its gradual improvement over the years offsets this drawback. Overall, the fundamentals support a sector premium for earnings quality and scale, but the current valuation already reflects a significant part of these strengths. For the target price, this is rather a moderately negative signal: the business is solid, but the multiples and debt burden do not justify an aggressive upward revision of the forecast. For an investor, Amgen looks like a reliable company with good operating momentum, but with limited upside due to an expensive valuation and balance sheet risks.

Amgen Inc.

Сильный индекс, значительно упал. Оптимистичный взгляд на свои позиции резко сменился на неуверенность.

Strong index, significantly down. An optimistic view of his position suddenly changed to uncertainty.

Сильный индекс, без изменений. Рынок не поддерживает быков.

Strong index, flat. The market does not support the bulls.

Сильный индекс, без изменений. Отток средств из лонгов на высоком уровне.

Strong index, flat. Outflow of funds from longs at a high level.

Amgen demonstrates strong profitability and growth, but its high valuation and significant debt limit the potential for further upside in the target price.

Key Points
Investors are increasingly seeking stable income amid geopolitical and economic uncertainty.
SCHD holds financially strong companies that can support sustained growth and appreciation.
With holdings across various sectors, SCHD helps reduce the risk when a single sector struggles.
Schwab U.S. Dividend Equity ETF (NYSEMKT: SCHD) is enjoying a massive breakout year, trading at roughly $34 at this writing and boasting a year-to-date (YTD) return of 29.29%. A look at SCHD's returns since its 2011 inception shows a steady record of healthy returns, but nothing quite like what the fund has experienced this year. For example:
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
Returns, Including Dividends
10 years
13.17%
Five years
10.01%
One year
29.53%
YTD
29.29%
For years, SCHD was respected and steady, but hardly spectacular. Between 2021 and 2025, the fund produced solid returns, but not enough to keep pace with the more impressive megacap tech surge. However, 2026 has been SCHD's year, with returns vaulting it into a leadership position among dividend-paying exchange-traded funds (ETFs).
What changed for 2026?
Notably, the dividend fund now holds a double-digit lead over the S&P 500, which has a YTD return of roughly 11%.
So, why the uptick in SCHD's value? It has to do with several macro and market forces, including:
Shift from growth to value: Investors, tired of paying high prices for AI and megacap tech stocks, are moving money into cheaper, less volatile companies that pay dividends, which is precisely what SCHD holds. Add current geopolitical instability and tariffs, and it's easy to understand why investors are looking for safer havens.
Underweight megacap tech: SCHD holdings don't include many of the giant tech names that have struggled so far this year. Without those holdings, the fund wasn't hurt when the tech sector cooled. Instead, SCHD's top holdings include companies like Abbott Labs, Amgen, ConocoPhillips, Chevron, and Home Depot.
March 2026 changes: SCHD's index was refreshed in March, adding more large, high-quality dividend names like UnitedHealth, Procter & Gamble, and Accenture to a roster that already included winners like Qualcomm and Texas Instruments. The additions helped boost returns.
SCHD appeals to investors due to its strong returns, healthy dividend yield, and low fees. Put simply, the ETF is having a winning year because the market currently favors the types of solid, dividend-paying companies SCHD is laser-focused on.
Should you buy stock in Schwab U.S. Dividend Equity ETF right now?
Before you buy stock in Schwab U.S. Dividend Equity ETF, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Schwab U.S. Dividend Equity ETF wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $417,413!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,341,294!*
Now, it’s worth noting Stock Advisor’s total average return is 950% — a market-crushing outperformance compared to 210% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
*Stock Advisor returns as of September 13, 2026.
Dana George has positions in Procter & Gamble. The Motley Fool has positions in and recommends Abbott Laboratories, Accenture Plc, Amgen, Chevron, Home Depot, Qualcomm, and Texas Instruments. The Motley Fool recommends ConocoPhillips and UnitedHealth Group and recommends the following options: long January 2028 $260 calls on Accenture Plc and short January 2028 $280 calls on Accenture Plc. The Motley Fool has a disclosure policy.

SCHD's Stunning Reversal: Schwab's Flagship Dividend ETF Is Up 29% and Climbing

Key Points
Amgen maintains a massive global footprint and generated over $8.1 billion in free cash flow during its latest fiscal year.
Revolution Medicines is a clinical-stage oncology specialist focused on high-stakes breakthrough therapies for RAS-addicted cancers.
Should investors prioritize the reliable income of a pharmaceutical giant or the explosive growth potential of a speculative biotech?
Investors choosing between Amgen (NASDAQ:AMGN) and Revolution Medicines (NASDAQ:RVMD) must weigh established cash flows against high-stakes clinical potential. Which of these healthcare players is the better addition to your portfolio today?
Amgen is a titan of the biotech world with a deep portfolio of marketed drugs and a history of returning capital to shareholders. Revolution Medicines represents the speculative side of the sector, focusing on breakthrough cancer research without any current revenue. Both companies offer exposure to medical innovation but through very different financial profiles.
The case for Amgen
Amgen focuses on developing and manufacturing therapies for serious illnesses in oncology, inflammation, and rare diseases. Within the biotech stocks landscape, the company primarily distributes its products through three major wholesalers: McKesson (NYSE:MCK), Cencora (NYSE:COR), and Cardinal Health (NYSE:CAH). Because these three customers account for nearly 77% of gross revenues, this customer concentration adds a layer of risk to the business.
In FY 2025, revenue reached nearly $36.7 billion, representing growth of approximately 9.9% over the previous year. Net income for the period was roughly $7.7 billion, which equals a net margin of 21%. This reflects a significant increase from the 12.2% net margin recorded in 2024, demonstrating the company's ability to maintain high profitability across its diverse drug portfolio.
As of its December 2025 balance sheet, the debt-to-equity ratio is roughly 6.3x. This ratio, which compares total debt to shareholder equity, indicates that the company carries significantly more debt than it has equity. The current ratio, which measures the ability to pay short-term debts with current assets, is approximately 1.1x. Free cash flow, which is the cash left after paying for capital projects, reached close to $8.1 billion in FY 2025.
The case for Revolution Medicines
Revolution Medicines is a global oncology company advancing a pipeline of therapies designed to target RAS-addicted cancers. It currently operates as a clinical-stage firm, meaning it has not yet brought a product to market or generated commercial sales. The company relies on strategic collaborations for development, including a partnership with BeOne Medicines and a royalty arrangement with Royalty Pharma (NASDAQ:RPRX).
In FY 2025, the company reported revenue of $0.0 because it does not yet have any approved products for sale. This resulted in a net loss of around $1.1 billion for the fiscal year as it expanded its clinical trials. This net loss grew compared to the prior year, reflecting the high costs associated with bringing new cancer treatments through the regulatory process.
As of its December 2025 balance sheet, the company maintains a debt-to-equity ratio of approximately 0.1x. This indicates a very low level of debt relative to its equity. The current ratio is quite high at roughly 9.5x, providing a substantial cushion for near-term operating expenses. However, free cash flow was negative at approximately $913.7 million in FY 2025, as is common for biotech firms in the research phase.
Risk profile comparison
Amgen faces significant pricing pressures from both government and commercial entities, including recent Medicare price-setting for major products like ENBREL. The company is also navigating ongoing tax disputes with the IRS regarding how it allocates profits between the United States and Puerto Rico. Additionally, Amgen must defend its intellectual property against biosimilar competitors while managing potential cybersecurity threats to its patient data systems.
Revolution Medicines carries the risks typical of a younger biotech, including a lack of approved products and a limited operating history. The company faces a high failure rate in its clinical trials and may encounter resistance mutations that limit the effectiveness of its therapies. It also competes against much larger pharmaceutical giants such as AstraZeneca (NYSE:AZN) and Pfizer (NYSE:PFE), which have significantly greater resources for research and marketing.
Which stock would I buy in 2026?
I'd go with Revolution Medicines, and this is an exciting pick. To give Amgen credit, it is a dependable, dividend-paying biotech with multiple brands growing at a double-digit rate and a raised full-year outlook. For investors who want steady, predictable healthcare exposure, it is a solid choice.
But Revolution Medicines just achieved something extraordinary. Daraxonrasib became the first targeted therapy ever approved for metastatic pancreatic cancer, one of the deadliest and hardest-to-treat cancers, after clinical data showed it cut the risk of death by more than half. This marks a potential paradigm shift in oncology. The pipeline extends into lung cancer and other RAS-driven tumors, and a new partnership with Royalty Pharma provides the funding to pursue those opportunities without diluting shareholders further.
The stock has surged and losses are widening as commercial investment ramps up. But if you're a long-term investor comfortable with biotech risk, this is an opportunity to own a company at the forefront of a genuine medical breakthrough. That's a much stronger bet than owning steady profitability alone.
Should you buy stock in Amgen right now?
Before you buy stock in Amgen, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Amgen wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $409,917!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,341,724!*
Now, it’s worth noting Stock Advisor’s total average return is 942% — a market-crushing outperformance compared to 211% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
*Stock Advisor returns as of September 11, 2026.
Sara Appino has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Amgen, AstraZeneca Plc, and Pfizer. The Motley Fool recommends McKesson. The Motley Fool has a disclosure policy.

Amgen vs. Revolution Medicines: Which Healthcare Stock Is a Better Buy in 2026?

Key Points
Amgen provides a stable foundation with multi-billion dollar revenues and consistent cash flows.
CRISPR Therapeutics offers high growth potential through its pioneering gene-editing technology.
Should you choose the safety of a pharmaceutical giant or the speculative volatility of a biotech innovator?
Investors often face a choice between the stability of established giants and the high-stakes potential of clinical-stage innovators. Deciding between Amgen (NASDAQ:AMGN) and CRISPR Therapeutics (NASDAQ:CRSP) requires balancing immediate dividends against long-term scientific breakthroughs.
Amgen is a global leader in traditional drug manufacturing with a vast portfolio of approved therapies. In contrast, CRISPR Therapeutics is a pioneer in gene-editing technology, recently launching its first commercial product. This comparison explores which approach offers a more compelling opportunity for your portfolio in 2026.
The case for Amgen
Amgen develops medicines for heart disease, obesity, and rare diseases among healthcare stocks. Its portfolio includes treatments for inflammatory conditions and various cancers, serving patients in more than 100 countries. The company distributes products primarily through three wholesalers: McKesson (NYSE:MCK), Cencora (NYSE:COR), and Cardinal Health (NYSE:CAH). These three companies accounted for nearly 77% of worldwide gross revenues in 2025. Customer concentration like this adds a layer of risk to the business.
In FY 2025, revenue reached nearly $36.7 billion, representing a growth of approximately 9.9% over the previous year. The company reported a net income of close to $7.7 billion for the same period, indicating a net margin of roughly 21%, an improvement over the 12.2% seen in 2024. These figures reflect the steady demand for its core products despite a shifting regulatory landscape.
As of its December 2025 balance sheet, the debt-to-equity ratio is nearly 6.3x. This ratio shows how much debt a company uses relative to shareholder equity. The current ratio, which compares short-term assets to liabilities, is roughly 1.1x. Free cash flow, or the cash left after paying for capital expenditures, was nearly $8.1 billion in FY 2025.
The case for CRISPR Therapeutics
CRISPR Therapeutics AG focuses on revolutionary gene-editing therapies, most notably CASGEVY, which treats sickle cell disease and transfusion-dependent beta thalassemia. This therapy has already gained approval in multiple regions, including the U.S., the U.K., and the EU. The company relies heavily on a collaboration with Vertex (NASDAQ:VERX), which manages global development, manufacturing, and commercialization. Under this agreement, CRISPR Therapeutics AG receives roughly 40% of the revenue while Vertex retains 60% of the proceeds.
In FY 2025, revenue reached nearly $3.5 million, a decrease of approximately 90% compared to the prior year. This resulted in a net loss of close to $581.6 million. The company reported a net margin of roughly -16,569.8%, reflecting the high costs of bringing new gene therapies to market and the early stage of its commercial rollout.
As of its December 2025 balance sheet, the debt-to-equity ratio is approximately 0.2x. The current ratio is nearly 13.3x, suggesting the company has significant short-term liquidity to fund its research. Free cash flow was roughly negative $345.9 million in FY 2025, meaning the company spent more on operations and equipment than it brought in during the year.
Risk profile comparison
Amgen faces pressure from government policies like the Inflation Reduction Act, which has already led to price setting for drugs like ENBREL and Otezla. The company also deals with significant litigation risks, including tax disputes with the IRS and class action lawsuits following data breaches. Furthermore, intense competition from biosimilars following the loss of exclusivity for Prolia and XGEVA threatens its future revenue. Manufacturing is also highly concentrated in Puerto Rico, making the supply chain vulnerable to natural disasters.
CRISPR Therapeutics remains unprofitable and expects to continue incurring significant operating losses while requiring additional funding for its clinical programs. Because Vertex exercises substantial control over the CASGEVY program, CRISPR Therapeutics has limited ability to influence global marketing or pricing strategies. Additionally, the CRISPR/Cas9 technology is relatively unproven, carrying risks of unintended genomic consequences or adverse reactions. Ongoing intellectual property disputes with the Broad Institute and other parties also create uncertainty regarding the company's freedom to operate.
Valuation comparison
CRISPR Therapeutics AG carries a lower Forward P/E based on future earnings estimates, but its P/S ratio is much higher than that of Amgen.
Forward P/E
19.1x
23.4x
P/S ratio
6.5x
450.5x
Valuation metrics sourced from Financial Modeling Prep (FMP) and may differ from other data providers.
Which stock would I buy in 2026?
I'd go with Amgen, though recent developments at CRISPR make this a more interesting call than it would have been a year ago. CASGEVY's momentum keeps building and revenue is accelerating at a pace that keeps surprising analysts. Losses are narrowing as the commercial infrastructure scales. The pipeline beyond CASGEVY is expanding into cardiovascular disease and other areas, adding long-term optionality that is starting to look like an exciting second act for the company.
But CRISPR is still losing a substantial amount of money every quarter, and the entire investment case rests on continued commercial execution and pipeline success. For most investors, that is a lot of uncertainty to carry.
Amgen is the steadier, more predictable business. Multiple brands are growing at a double-digit rate, the full-year outlook has been raised, and the dividend keeps compounding year after year. Cheaper versions of some of its older drugs are entering the market, but Amgen has enough other growth drivers to absorb that pressure, and new drugs in development could add to the story down the road.
For a long-term investor who wants biotech exposure without betting everything on clinical outcomes, Amgen is the more comfortable place to put your money right now.
Should you buy stock in Amgen right now?
Before you buy stock in Amgen, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Amgen wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $409,917!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,341,724!*
Now, it’s worth noting Stock Advisor’s total average return is 942% — a market-crushing outperformance compared to 211% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
*Stock Advisor returns as of September 11, 2026.
Sara Appino has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Amgen. The Motley Fool recommends CRISPR Therapeutics and McKesson. The Motley Fool has a disclosure policy.

Amgen vs. CRISPR Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?

In early trading on Friday, shares of Honeywell International topped the list of the day's best performing Dow Jones Industrial Average components, trading up 7.5%. Year to date, Honeywell International registers a 42.2% gain.
And the worst performing Dow component thus far on the day is Amgen, trading down 0.1%. Amgen Inc is showing a gain of 16.7% looking at the year to date performance.
Two other components making moves today are UnitedHealth Group, trading flat on the day, and Cisco Systems, trading up 2.1% on the day.
VIDEO: Dow Movers: AMGN, HONIV

Dow Movers: AMGN, HONIV

Key Points
Amgen delivers strong profitability and a diverse portfolio of established chronic disease treatments.
Moderna continues to transition its business as it pivots from pandemic products to a broader mRNA pipeline.
Which healthcare stock is the more compelling investment for your portfolio as 2026 unfolds?
Should you bet on an established giant or a pipeline-driven innovator? This comparison examines Amgen (NASDAQ:AMGN) and Moderna (NASDAQ:MRNA) to see which stock is a better buy today.
Amgen is a veteran in the drug manufacturing world, focusing on long-term stability and diverse treatments for chronic conditions. Moderna is a biotechnology pioneer that transformed during the pandemic and is now pivoting toward a broader mRNA platform. Both companies operate in a competitive environment, but they offer very different risk and reward profiles for investors.
The case for Amgen
Amgen operates by discovering and marketing medicines for serious conditions such as heart disease, obesity, and cancer. The company functions within the biotech stocks category, serving approximately 17 million patients globally. Its commercial success depends heavily on three distributors: McKesson (NYSE:MCK), Cencora (NYSE:COR), and Cardinal Health (NYSE:CAH). These three partners accounted for 77% of gross revenues in 2025. Customer concentration like this adds a layer of risk to the business.
In its latest annual report, filed for FY 2025, revenue reached nearly $36.7 billion. This represents a growth rate of roughly 9.9% compared to the previous year. Amgen reported net income of approximately $7.7 billion for the same period. The company achieved a net margin of 21%, which measures the portion of revenue that remains as profit after all expenses are paid.
As of its December 2025 balance sheet, the debt-to-equity ratio was 6.3x. This ratio indicates that total debt is more than six times the value of shareholder equity. Amgen also reported a current ratio of 1.1x, suggesting it has enough short-term assets to cover its immediate debts. Free cash flow, which is operating cash minus capital spending, was nearly $8.1 billion in FY 2025.
The case for Moderna
Moderna focuses on developing mRNA medicines for infectious diseases, cancer, and rare conditions. Its portfolio includes vaccines such as Spikevax and mRESVIA, with the mNEXSPIKE product leading its sales in the United States retail channel. The company also works with international partners to expand its reach. For instance, it has a collaboration with Merck (NYSE:MRK) to develop specialized cancer treatments. Sales remain highly dependent on the accuracy of vaccine demand forecasts.
In its latest annual report, filed for FY 2025, revenue was close to $1.9 billion. This was a decline of approximately 39.2% from the prior year as demand for pandemic-related products shifted. Moderna reported a net loss of nearly $2.8 billion for the fiscal year. This resulted in a negative net margin of 145.2%, reflecting the high costs of research and development relative to current sales.
Based on its December 2025 balance sheet, the debt-to-equity ratio was roughly 0.2x. This indicates a much lower reliance on debt compared to Amgen. The company maintained a current ratio of 3.3x, showing a high level of liquid assets. However, free cash flow was negative $2.1 billion for FY 2025, as the company continued to invest heavily in its future drug pipeline.
Risk profile comparison
Amgen faces significant risks from government regulation regarding drug pricing, including provisions in the Inflation Reduction Act. The company also faces pressure from biosimilars as patents for major products like Prolia and XGEVA have expired. Litigation risks remain elevated, including an ongoing tax dispute with the IRS regarding profit allocation in Puerto Rico. Furthermore, Amgen is vulnerable to infrastructure disruptions at its primary manufacturing sites in California and Puerto Rico.
Moderna faces intense competition from established pharmaceutical giants such as Pfizer (NYSE:PFE), Sanofi (NASDAQ:SNY), and GSK (NYSE:GSK). Its business carries high clinical development risk because mRNA technology is still a relatively novel field with complex manufacturing requirements. Financial results are also impacted by legal costs, such as a patent settlement with Arbutus Biopharma (NASDAQ:ABUS). Additionally, Moderna relies on single-source suppliers for certain raw materials, which creates supply chain vulnerability.
Valuation comparison
Forward P/E
19.1x
N/A
P/S ratio
6.5x
29.7x
Valuation metrics sourced from Financial Modeling Prep (FMP) and may differ from other data providers.
Which stock would I buy in 2026?
I'd go with Amgen, and the case for it is straightforward. Multiple brands are growing at a double-digit rate, the full-year outlook has been raised, and the dividend keeps growing. That combination is hard to find in biotech right now. Some of its older drugs face competition from cheaper alternatives, but the rest of the business is strong enough to carry the weight, and new drugs in development could add to the growth story down the road.
Moderna is doing interesting work across a broad pipeline, and its mRNA flu vaccine just received a unanimous positive recommendation from the FDA's advisory committee. But the company is still losing a substantial amount of money every quarter, current revenue is tiny relative to its ambitions, and the norovirus vaccine program just hit a setback in its phase 3 trial. The entire investment case rests on clinical trial outcomes that may be years away.
For a long-term investor, owning a profitable, dividend-paying biotech that is already executing beats waiting on a pipeline that still has a lot to prove.
Should you buy stock in Amgen right now?
Before you buy stock in Amgen, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Amgen wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $410,024!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,372,815!*
Now, it’s worth noting Stock Advisor’s total average return is 950% — a market-crushing outperformance compared to 211% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
*Stock Advisor returns as of September 10, 2026.
Sara Appino has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Amgen, Merck, Moderna, and Pfizer. The Motley Fool recommends GSK and McKesson. The Motley Fool has a disclosure policy.

Amgen vs. Moderna: Which Healthcare Stock Is a Better Buy in 2026?

Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the SPDR Dow Jones Industrial Average ETF Trust (Symbol: DIA) where we have detected an approximate $501.7 million dollar inflow -- that's a 1.1% increase week over week in outstanding units (from 85,942,867 to 86,892,867). Among the largest underlying components of DIA, in trading today Amgen Inc (Symbol: AMGN) is up about 0.1%, Travelers Companies Inc (Symbol: TRV) is up about 0.2%, and Sherwin-Williams Co (Symbol: SHW) is lower by about 0.7%. For a complete list of holdings, visit the DIA Holdings page » The chart below shows the one year price performance of DIA, versus its 200 day moving average:
Looking at the chart above, DIA's low point in its 52 week range is $450.44 per share, with $546.75 as the 52 week high point — that compares with a last trade of $524.44. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average ».
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Further DIA Research:

Notable ETF Inflow Detected - DIA, AMGN, TRV, SHW

Looking at options trading activity among components of the S&P 500 index, there is noteworthy activity today in Amgen Inc (Symbol: AMGN), where a total volume of 24,919 contracts has been traded thus far today, a contract volume which is representative of approximately 2.5 million underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 111.4% of AMGN's average daily trading volume over the past month, of 2.2 million shares. Especially high volume was seen for the $350 strike put option expiring November 20, 2026, with 3,010 contracts trading so far today, representing approximately 301,000 underlying shares of AMGN. Below is a chart showing AMGN's trailing twelve month trading history, with the $350 strike highlighted in orange:
Vistra Corp (Symbol: VST) saw options trading volume of 33,396 contracts, representing approximately 3.3 million underlying shares or approximately 84.7% of VST's average daily trading volume over the past month, of 3.9 million shares. Particularly high volume was seen for the $120 strike put option expiring November 20, 2026, with 2,635 contracts trading so far today, representing approximately 263,500 underlying shares of VST. Below is a chart showing VST's trailing twelve month trading history, with the $120 strike highlighted in orange:
And Dell Technologies Inc (Symbol: DELL) saw options trading volume of 63,905 contracts, representing approximately 6.4 million underlying shares or approximately 76.8% of DELL's average daily trading volume over the past month, of 8.3 million shares. Especially high volume was seen for the $525 strike put option expiring September 11, 2026, with 1,901 contracts trading so far today, representing approximately 190,100 underlying shares of DELL. Below is a chart showing DELL's trailing twelve month trading history, with the $525 strike highlighted in orange:
For the various different available expirations for AMGN options, VST options, or DELL options, visit StockOptionsChannel.com.
Further AMGN Research:

Notable Tuesday Option Activity: AMGN, VST, DELL

(RTTNews) - Amgen Inc.(AMGN) on Tuesday reported that the Phase 3 DeLLphi-305 study, which evaluated IMDELLTRA (tarlatamab-dlle) in combination with AstraZeneca PLC's(AZN) Imfinzi (durvalumab) versus durvalumab alone as first-line maintenance treatment for people with extensive-stage small cell lung cancer (ES-SCLC), met its primary endpoint of overall survival.
SCLC is one of the most aggressive forms of lung cancer, accounting for approximately 13-15% of the more than 2.6 million lung cancer cases diagnosed worldwide each year, as per company estimates. According to the company, median overall survival with the current standard of care is approximately one year, and only about 40% of patients receive second-line therapy.
IMDELLTRA and Trial Details
IMDELLTRA (tarlatamab-dlle) is a targeted immunotherapy engineered by Amgen researchers to bind to DLL3 on tumour cells and CD3 on T cells, activating T cells to kill DLL3-expressing SCLC cells.
IMDELLTRA is already approved by the FDA for the treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy.
The DeLLphi-305 trial is a global phase 3, randomised, open-label clinical trial evaluating the efficacy and safety of IMDELLTRA in combination with durvalumab versus durvalumab alone as first-line maintenance treatment for patients with ES-SCLC who had not progressed after treatment with durvalumab, platinum-based chemotherapy, and etoposide.
Amgen sponsors the trial, with AstraZeneca providing partial funding and durvalumab.
Key Findings
According to the company, the phase 3 DeLLphi-305 study met its primary endpoint at a pre-specified interim analysis, showing a statistically significant and clinically meaningful improvement in overall survival with IMDELLTRA (tarlatamab-dlle) plus Imfinzi (durvalumab) compared with durvalumab alone. In addition, the study showed a statistically significant and clinically meaningful improvement in progression-free survival (PFS) and objective response rate (ORR) among patients treated with IMDELLTRA plus durvalumab.
The company said the safety profile of IMDELLTRA in combination with durvalumab was consistent with the known safety profiles of the individual medicines.
According to Amgen, DeLLphi-305 is the first Phase 3 study to include a Bispecific T-cell Engager (BiTE) therapy to demonstrate an overall survival benefit in the first-line maintenance setting for ES-SCLC.
Amgen plans to present detailed DeLLphi-305 data at an upcoming international medical congress and share them with regulatory authorities.
Stock Performance
AMGN has traded between $269.77 and $447.03 over the last year. The stock is currently down 9% at $397.79.
AZN has traded between $145.80 and $212.71 over the last year. AZN is currently down 0.71% at $161.54.
For more such biotech news, visit www.rttnews .com

Amgen And AstraZeneca's IMDELLTRA-Imfinzi Combo Shows Survival Benefit In Phase 3 ES-SCLC Study

In early trading on Tuesday, shares of Honeywell International topped the list of the day's best performing components of the S&P 500 index, trading up 7.5%. Year to date, Honeywell International registers a 42.2% gain.
And the worst performing S&P 500 component thus far on the day is Amgen, trading down 7.2%. Amgen is showing a gain of 23.9% looking at the year to date performance.
Two other components making moves today are Howmet Aerospace, trading down 5.6%, and Intel, trading up 5.6% on the day.

S&P 500 Movers: AMGN, HONIV

In early trading on Tuesday, shares of Honeywell International topped the list of the day's best performing Dow Jones Industrial Average components, trading up 7.5%. Year to date, Honeywell International registers a 42.2% gain.
And the worst performing Dow component thus far on the day is Amgen, trading down 7.2%. Amgen is showing a gain of 23.9% looking at the year to date performance.
Two other components making moves today are Salesforce, trading down 4.2%, and Chevron, trading up 2.1% on the day.
VIDEO: Dow Movers: AMGN, HONIV